SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Board appointments

31 Mar 2014 07:00

RNS Number : 5183D
Frontier IP Group plc
31 March 2014
 



 

AIM: FIPP

 

Frontier IP Group plc

("Frontier IP" or "the Company")

 

Board changes

 

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce two Board appointments, which both take immediate effect. James Fish has been appointed to the Company as Finance Director and Michael Bourne has been appointed to the Company as a Non-Executive Director.

 

James Fish, a chartered accountant, has over 25 years' experience in senior financial positions and a wide range of commercial experience including venture capital funded small/medium-sized enterprises and start-up companies. He was latterly interim Finance Director at The One Place Capital Limited, an online technology start-up. He qualified as a chartered accountant with KPMG and holds a degree in Accounting and Finance from Heriot Watt University, Edinburgh. James's appointment enables Marilyn Cole to step down as Finance Director and Company Secretary. James will also be appointed Company Secretary.

 

Michael Bourne has almost 30 years' experience in investment management and particular expertise in technology, life sciences and clean technology. He is currently Partner of Accretion Capital LLP and a Director of Cygna Negra Limited and Cygna Negra Malta Limited. He is also an Advisory Board Member of V2R, the US technology transfer venture company. Prior to these roles, in 1995, he founded asset management company, Reabourne Technology Investments Limited, where he was also Chief Investment Officer. For nine years until 2009, he was also a member of the techMARK Advisory Committee.

 

Neil Crabb, Chief Executive of Frontier IP, said,

 

"We are delightedto welcome Jim as Finance Director and Mike as a Non-executive Director. Their appointments strengthen our Board as we continue Frontier IP's development.

 

Jim brings over 25 years' experience as a senior finance professional and his involvement with start-up companies as well as venture capital funded SMEs is especially useful. Mike has substantial experience in investment management and his expertise in the clean energy and life sciences sectors also represents an excellent fit with Frontier IP's activities.

 

As well as welcoming Jim and Mike, I would also like to acknowledge Marilyn's significant contribution to Frontier IP during her time as Finance Director of the Company. She leaves with the Board's best wishes and grateful thanks."

 

The following information is required to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

James Milne Fish, aged 56, is or has been a director or partner of the following companies during the previous five years:

 

Current Directorships / Partnerships:

Directorships / Partnerships held within the previous five years:

FD Support Limited

 

In addition, as an interim finance director, Mr Fish has undertaken in the previous five years a finance director role with The One Place Capital Limited, McLaren Software Group Limited and Photo Therapeutics Group Limited. Photo Therapeutics Group Limited entered into a Voluntary Members Liquidation in March 2009, after the return of funds to shareholders following a trade sale of the operating subsidiary.

 

Mr Fish is a member of the Institute of Chartered Accountants of Scotland.

 

Mr Fish currently has no beneficial interest in the share capital of the Company.

 

There are no other matters which are required to be announced with regard to the appointment of Mr Fish under paragraph (g) of Schedule 2 of the AIM Rules.

 

Michael Gerald Bourne, aged 55, is or has been a director or partner of the following companies during the previous five years:

 

Current Directorships / Partnerships:

Directorships / Partnerships held within the previous five years:

Accretion Capital LLP

MGB Technology Consulting Ltd

Coombe Wood Lawn Tennis Club Limited

Cygna Negra Limited

Cygna Negra Malta Limited

 

Mr Bourne currently has no beneficial interest in the share capital of the Company.

 

There are no other matters which are required to be announced with regard to the appointment of Mr Bourne under paragraph (g) of Schedule 2 of the AIM Rules.

 

 

Enquiries

 

Frontier IP Group Plc

0131 220 9491

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

020 7894 7000

Mark Percy / Catherine Leftley, Corporate Finance

David Banks / Paul Jewell, Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

020 7469 0935

Jon Levinson / Lucy Williams

KTZ Communications

020 3178 6378

Katie Tzouliadis / Deborah Walter

 

 

Notes to Editor:

 

Frontier IPspecialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes. www.frontierip.co.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADVLFLZXFEBBK
Date   Source Headline
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.